Skip to main content

Dubow Adam's Form 4 filing

Day One Biopharmaceuticals, Inc. (DAWN) · filed Nov 18, 2025

Accession no.
0001744507-25-000006
Filed
Nov 18, 2025
Trade date
Nov 15-17, 2025
Filing delay
3 days
Rule 10b5-1 plan
Not checked

This filing lists 5 non-derivative transactions and 4 derivative transactions. Open-market sales total $38.5K. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Dubow AdamCIK 0001744507Officer (Gen Counsel & Secretary)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 15, 2025Common StockMOption exerciseAcquired+2,963––57,821Direct
Nov 15, 2025Common StockMOption exerciseAcquired+1,750––59,571Direct
Nov 15, 2025Common StockMOption exerciseAcquired+3,687––63,258Direct
Nov 15, 2025Common StockMOption exerciseAcquired+3,687––66,945Direct
Nov 17, 2025Common StockSSaleDisposed−4,319$8.91−$38,482.2962,626Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 15, 2025Common StockMOption exerciseDisposed−2,963$0.00$011,852Direct
Nov 15, 2025Common StockMOption exerciseDisposed−1,750$0.00$07,000Direct
Nov 15, 2025Common StockMOption exerciseDisposed−3,687$0.00$029,504Direct
Nov 15, 2025Common StockMOption exerciseDisposed−3,687$0.00$044,252Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)